These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 26749374)
1. Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells. Mise N; Takami M; Suzuki A; Kamata T; Harada K; Hishiki T; Saito T; Terui K; Mitsunaga T; Nakata M; Ikeuchi T; Nakayama T; Yoshida H; Motohashi S Cancer Sci; 2016 Mar; 107(3):233-41. PubMed ID: 26749374 [TBL] [Abstract][Full Text] [Related]
2. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner. Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315 [TBL] [Abstract][Full Text] [Related]
3. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control. Guan P; Schaub R; Nichols KE; Das R Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464 [TBL] [Abstract][Full Text] [Related]
4. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283 [TBL] [Abstract][Full Text] [Related]
5. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody. Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408 [TBL] [Abstract][Full Text] [Related]
6. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma. Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110 [TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Moreno M; Mol BM; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ Cancer Lett; 2008 Dec; 272(1):70-6. PubMed ID: 18684557 [TBL] [Abstract][Full Text] [Related]
8. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481 [TBL] [Abstract][Full Text] [Related]
9. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control. Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y Front Immunol; 2018; 9():1266. PubMed ID: 29928278 [TBL] [Abstract][Full Text] [Related]
10. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells. Yang G; Artiaga BL; Lewis ST; Driver JP Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168 [TBL] [Abstract][Full Text] [Related]
11. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
12. Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity. Andrews K; Hamers AAJ; Sun X; Neale G; Verbist K; Tedrick P; Nichols KE; Pereira S; Geraghty DE; Pillai AB Cytotherapy; 2020 May; 22(5):276-290. PubMed ID: 32238299 [TBL] [Abstract][Full Text] [Related]
13. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL. Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma. Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682 [TBL] [Abstract][Full Text] [Related]
15. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337 [TBL] [Abstract][Full Text] [Related]